Preferences help
enabled [disable] Abstract
Number of results
2009 | 56 | 4 | 733-737
Article title

Influence of megestrol acetate on nutrition and inflammation in dialysis patients - preliminary results

Title variants
Languages of publication
Malnutrition is a common clinical problem in dialysis patients. So far the management of malnutrition in this population has not been fully successful. The aim of the study was to evaluate the efficacy and safety of use of megestrol acetate suspension in malnourished dialysis patients. Twenty-six hypoalbuminemic (albumin ≤ 3.8 g/dl) dialysis patients took 160 mg of megestrol acetate daily for a period of two months. Anthropometry (dry weight, body mass index) and biochemical measurements of nutrition (serum albumin, triglycerides, total cholesterol) and inflammation (hsCRP, IL-1β, IL-6) were performed on a monthly basis. The treatment led to a statistically significant increase (P < 0.05) in anthropometry and albumin concentration, with no statistically significant changes in total cholesterol, triglycerides and indices of inflammation. Side effects included overhydration, diarrhoea and hyperglycaemia. Thus, megestrol acetate may be an effective therapeutic agent in improving the nutritional status of carefully selected dialysis patients, while it might not mitigate inflammation. Because of the prevalent side effects it must be monitored closely.
Physical description
  • Palliative Medicine Department, Medical University of Gdańsk, Gdańsk, Poland
  • Palliative Medicine Department, Medical University of Gdańsk, Gdańsk, Poland
  • Chair of Clinical Nutrition, Medical University of Gdańsk, Gdańsk, Poland
  • Quality of Life Research Department, Medical University of Gdańsk, Gdańsk, Poland
  • Chair of Clinical Nutrition, Medical University of Gdańsk, Gdańsk, Poland
  • Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland
  • Boccanfuso JA, Hutton M, McAllister B (2000) The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 10: 36-43.
  • Burrowes JD, Bluestone PA, Wang J, Pierson RN Jr (1999) The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient. J Ren Nutr 9: 89-94.
  • Costero O, Bajo MA, del Peso G, Gil F, Aguilera A, Ros S, Hevia C, Selgas R (2004) Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate. Adv Perit Dial 20: 209-212.
  • de Mutsert R, Grootendorst DC, Axelsson J, Boeschoten EW, Krediet RT, Dekker FW and the NECOSAD Study Group (2008) Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 23: 2957-2964.
  • Dwyer JT, Larive B, Leung J, Rocco M, Burrowes JD, Chumlea, Frydrych A, Kusek JW, Uhlin L, HEMO Study Group (2002) Nutritional status affects quality of life in hemodialysis (HEMO) study patients at baseline. J Ren Nutr 12: 213-223.
  • Jatoi A, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL (2002) Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 10: 71-75.
  • Kalantar-Zadeh K, Ikizler A, Block G, Avram M, Kopple J (2003) Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42: 864-881.
  • Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H Jr, Kopple JD, Greenland S (2005) Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 20: 1880-1888.
  • Kalantar-Zadeh K, Kopple J, Block G, Humphreys M (2001) Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 12: 2797-2806.
  • Lien YH, Ruffenach SJ (1996) Low dose megestrol increases serum albumin in malnourished dialysis patients. Int J Artif Organs 19: 147-150.
  • Lopez AP, Figuls MR, Cuchi GU, Berenstein EG, Pasies BA, Alegre MB, Herdman M (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 27: 360-369.
  • Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC (1998a) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25: 45-52.
  • Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC (1998b) Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 9: 99-106.
  • Monfared A, Heidarzadeh A, Ghaffari M, Akbarpour M (2009) Effect of megestrol acetate on serum albumin level in malnourished dialysis patients. J Ren Nutr 19: 167-171.
  • Murtagh FE, Addington-Hall J, Higginson IJ (2007) The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 14: 82-99.
  • Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C (2005) Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 15: 345-355.
  • Rashid Qureshi A, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, Bergström J (2002) Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13: S28-S36.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.